Background. Little is known about the outcomes of patients who are initiated on vancomycin as empiric monotherapy relative to antistaphyloccal BL therapy for MSSA BSIs. The purpose of this study was to evaluate outcomes of patients with MSSA BSIs who were treated with vancomycin monotherapy empirically compared to those who also received an antistaphylococcal BL.
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Study Results

Variable
Vancomycin monotherapy (N=20) Empiric BL (N=75) P-Value On multivariate analysis, only APACHE-II score was associated with clinical failure.
Methods. This was a single-center retrospective study of patients with MSSA BSIs from April 2008-December 2013. Inclusion criteria were: receipt of ≥48 hours of empiric therapy; ≥1 positive blood culture with MSSA; first positive culture drawn within 24 hours of starting empiric antibiotics. Exclusion criteria consisted of: use of anti-MRSA therapy for concomitant infection; polymicrobial BSI; use of other agents active against MSSA. The primary endpoint was clinical failure, a composite of 30-day mortality and persistent BSI ≥7 days. Logistic regression was performed to determine factors associated with the endpoint.
Results. 339 charts of patients with S. aureus BSI were screened and 75 of these patients were included in the final analysis.
Conclusion. This study does not show a significantly increased risk of clinical failure in patients who are treated with vancomycin monotherapy empirically. The lack of significant differences between groups may be due to insufficient power to detect a difference; therefore, a larger study evaluating the influence of empiric antibiotic choice for MSSA BSI is warranted.
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